GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spago Nanomedical AB (OSTO:SPAGO) » Definitions » EV-to-Revenue

Spago Nanomedical AB (OSTO:SPAGO) EV-to-Revenue : 5.94 (As of May. 25, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Spago Nanomedical AB EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Spago Nanomedical AB's enterprise value is kr8.72 Mil. Spago Nanomedical AB's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was kr1.47 Mil. Therefore, Spago Nanomedical AB's EV-to-Revenue for today is 5.94.

The historical rank and industry rank for Spago Nanomedical AB's EV-to-Revenue or its related term are showing as below:

OSTO:SPAGO' s EV-to-Revenue Range Over the Past 10 Years
Min: -19.72   Med: 1243.52   Max: 10403.19
Current: 5.95

During the past 13 years, the highest EV-to-Revenue of Spago Nanomedical AB was 10403.19. The lowest was -19.72. And the median was 1243.52.

OSTO:SPAGO's EV-to-Revenue is ranked better than
57.27% of 1039 companies
in the Biotechnology industry
Industry Median: 8.18 vs OSTO:SPAGO: 5.95

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-25), Spago Nanomedical AB's stock price is kr0.24. Spago Nanomedical AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was kr0.01. Therefore, Spago Nanomedical AB's PS Ratio for today is 24.00.


Spago Nanomedical AB EV-to-Revenue Historical Data

The historical data trend for Spago Nanomedical AB's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spago Nanomedical AB EV-to-Revenue Chart

Spago Nanomedical AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10,109.83 706.36 220.02 -4.56 13.68

Spago Nanomedical AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.67 36.92 7.90 13.68 22.45

Competitive Comparison of Spago Nanomedical AB's EV-to-Revenue

For the Biotechnology subindustry, Spago Nanomedical AB's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Spago Nanomedical AB's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spago Nanomedical AB's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Spago Nanomedical AB's EV-to-Revenue falls into.



Spago Nanomedical AB EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Spago Nanomedical AB's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=8.715/1.466
=5.94

Spago Nanomedical AB's current Enterprise Value is kr8.72 Mil.
Spago Nanomedical AB's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr1.47 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Spago Nanomedical AB  (OSTO:SPAGO) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Spago Nanomedical AB's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.24/0.01
=24.00

Spago Nanomedical AB's share price for today is kr0.24.
Spago Nanomedical AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.01.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Spago Nanomedical AB EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Spago Nanomedical AB's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Spago Nanomedical AB (OSTO:SPAGO) Business Description

Traded in Other Exchanges
Address
Scheelevagen 22, Lund, SWE, SE-223 63
Spago Nanomedical AB is a nanomedicine company in the field of cancer diagnosis and treatment. The company's product includes SpagoPix and Tumorad. The SpagoPix product aims to improve cancer diagnosis with magnetic resonance imaging through previous detection of tumors and metastases. The Tumorad products focuses on the development of a completely new form of radionuclide therapy for tumor selective radiation therapy of cancer. The company development projects are based on a platform of polymeric materials with varoious properties for precise diagnosis and treatment of life threatening and debilitating diseases.

Spago Nanomedical AB (OSTO:SPAGO) Headlines

No Headlines